Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children
Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated Over a Period of 3 Years or 5 Years if Applicable, in Comparison With a Historic Cohort of Non-treated Children With Hypochondroplasia
Sponsor: Merck KGaA, Darmstadt, Germany
Listed as NCT01111019, this PHASE2 trial focuses on Hypochondroplasia and remains completed. Sponsored by Merck KGaA, Darmstadt, Germany, it has been updated 11 times since 2006, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2022 — Mar 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Jan 2022 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2019 — Mar 2019 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2019 [monthly]
Completed PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jul 2017 — Dec 2017 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Mar 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck KGaA, Darmstadt, Germany
- Merck Serono S.A.S, France
For direct contact, visit the study record on ClinicalTrials.gov .